These are to:
- drive therapeutic breakthroughs in immune-related diseases
- explore new strategies for the control of globally important pathogens
- increase the likelihood of discovering important, high-value, new medicines in the UK by enhancing interactions between academia and the pharmaceutical industry.
The project will focus on autoimmune and inflammatory disease – for example Type 1 diabetes and inflammatory bowel disease – and the looming threat posed by antimicrobial resistance.
Page last updated 26 February 2015